Evidence of synergetic efficacy of radioisotope nano-carrier drugs with immunotherapy

Background: Since immunotherapy first emerged as a novel, safe, and effective cancer therapeutic, it was expected to bring new era against cancer. Yet, has fallen short solid tumors, one of the most common causes death, due immune cell’s limitation in penetrating tumor masses. To compensate for traditional therapy, many methods have such antibody drug conjugates (ADC), which challenged by reactive resistance, radioisotope therapy (RIT), faced limitations delivery. with innovative binding improvements, we may now solution. Based on iron oxide material-based nano-carrier’s radioisotope-binding technology, our is capable delivering payload target without losing isotopes. It also functions platform interchangeably compatible all types radioisotopes targeting ligands. Moreover, nano-carrier technology holds tremendous potential improving immunotherapeutic efficacy patients. In contrast conventional oncological immunotherapies, can design nanomaterials trigger specific tumoricidal effects, thereby cell accessibility major sites metastasis optimizing antigen presentation inducing persistent response tissues bone, lungs, lymph nodes. Materials methods: Efficacy tests were carried out female balb/c-nu mice. Subcutaneous xenograft models created implanting ovarian/triple negative breast cells right flank test animals. Resulting tumors monitored measured using caliper three five weeks. Synergetic anti-cancer effects drugs PD-1/PD-L1 inhibitors observed. Results: Our results demonstrated that combination radionuclide (iron oxide) synergetically higher compared single treatment. This experiment showed efficiency direct in-vivo from drugs. We verified this intensely affect cells, mice models, at non-clinical level, increasing its survival rate. Amongst tested lines, treated combined had rates growth inhibition regression no significant toxicity Conclusions: found promising based be next generation solution cancers. test, drug+immunotherapy. precision secure delivery payload(radioisotopes) objective able reach high efficacy. No conflict interest.